Features Screener Stocks Charts
Sign In Sign Up

LINCOLN Pharmaceuticals Cash Flow Statement

NSE:LINCOPH | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.85x

LINCOPH's operating cash flow covered 85% of net income in FY 2025. Some earnings may be tied up in working capital.

Free Cash Flow

₹739.86M

LINCOPH's free cash flow was ₹739.86M in FY 2025, up 211.6% from FY 2024.

Dividend Coverage

20.5x

LINCOPH's free cash flow covered dividends 20.5x in FY 2025, leaving room for reinvestment or debt reduction.

CapEx Intensity

20.5%

Capital expenditure was 20.5% of operating cash flow in FY 2025 for LINCOPH, indicating a capital-light business.

2-year LINCOPH cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 1.22B 1.09B
Cash flow Operating Activities 632.17M 930.16M
Investments in PPE -394.76M -190.29M
Cash flow Investing Activities -573.41M -789.47M
Dividend Paid -30.05M -36.05M
Cash flow Financing Activities -51.80M -64.02M
Cash at beginning of period 50.52M 57.47M
Cash at end of period 57.47M 134.14M
Free Cash Flow 237.41M 739.86M

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025